Clinical Trial Update: Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating human anti-CD19 CAR-T cells for relapsed or refractory lymphoid malignancies is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD19 CAR T cells (CD19-directed CAR T cells)

Snippet

Sponsor: Benjamin Tomlinson | Conditions: Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING